Literature DB >> 31784349

Clinical Characteristics and Risk of Exacerbations Associated With Different Diagnostic Criteria of Asthma-COPD Overlap.

Juan José Soler-Cataluña1, Laura Novella2, Cristina Soler3, María Luisa Nieto4, Violeta Esteban4, Fernando Sánchez-Toril4, Marc Miravitlles5.   

Abstract

INTRODUCTION: There is currently no universally accepted definition of asthma-COPD overlap (ACO).
OBJECTIVE: To compare the prevalence of ACO in patients with asthma or COPD, and to assess their clinical characteristics and the capacity of the different definitions to predict the risk of exacerbation.
METHOD: Prospective observational study with a 12-month follow-up in an asthma cohort and a COPD cohort. Four diagnostic criteria were compared: A) the Spanish 2012 consensus; B) the 2016 international consensus; C) the 2017 consensus between the Spanish COPD guidelines (GesEPOC) and GEMA asthma guidelines; and D) the single criterion of ≥300eosinophils/μL, proposed by GOLD 2019. The risk of exacerbations was evaluated in each group.
RESULTS: A total of 345 patients were included, 233 (67.5%) with COPD and 112 (32.5%) with asthma, aged 63±14 years, 70.4% men. Fifteen (4.3%) patients met the criteria for ACO according to the criteria described under A above; 30 (8.7%) with the criteria of B; 118 (34.2%) with the criteria of C; and 97 (28.1%), with the D criterion. The ACO-COPD subtype were older, had worse lung function, and an increased risk of exacerbation compared with the ACO-asthma group. Of all the definitions evaluated, those which distinguished a higher risk of exacerbations were the GesEPOC-GEMA consensus and the GOLD proposal.
CONCLUSIONS: The prevalence of ACO varies enormously depending on the diagnostic criteria used. The ACO population is heterogeneous, and the ACO-COPD subtype is very different from the ACO-asthma subtype. The definitions that include eosinophilia identify ACO patients with a greater risk of exacerbation.
Copyright © 2020. Publicado por Elsevier España, S.L.U.

Entities:  

Keywords:  Asma; Asthma; Asthma-COPD overlap; COPD; EPOC; Exacerbaciones; Exacerbations; Solapamiento asma-EPOC

Mesh:

Year:  2019        PMID: 31784349     DOI: 10.1016/j.arbres.2019.08.023

Source DB:  PubMed          Journal:  Arch Bronconeumol (Engl Ed)        ISSN: 0300-2896            Impact factor:   4.872


  11 in total

1.  Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD.

Authors:  Jun Tang; Víctor Curull; Xuejie Wang; Coral Ampurdanés; Xavier Duran; Lara Pijuan; Alberto Rodríguez-Fuster; Rafael Aguiló; José Yélamos; Esther Barreiro
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

2.  B Cells and Tertiary Lymphoid Structures Influence Survival in Lung Cancer Patients with Resectable Tumors.

Authors:  Jun Tang; Daniel Ramis-Cabrer; Víctor Curull; Xuejie Wang; Mercé Mateu-Jiménez; Lara Pijuan; Xavier Duran; Liyun Qin; Alberto Rodríguez-Fuster; Rafael Aguiló; Esther Barreiro
Journal:  Cancers (Basel)       Date:  2020-09-16       Impact factor: 6.639

3.  Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD.

Authors:  Mònica Monteagudo; Miriam Barrecheguren; Iryna Solntseva; Nafeesa Dhalwani; Alison Booth; Alexa Nuñez; Dimitra Lambrelli; Marc Miravitlles
Journal:  NPJ Prim Care Respir Med       Date:  2021-03-22       Impact factor: 2.871

4.  Economic Impact of Low Adherence to COPD Management Guidelines in Spain.

Authors:  Marc Miravitlles; Alexandra Solé; Helena Aguilar; Ana Ampudia; Jaume Costa-Samarra; Maria Mallén-Alberdi; Diana Nieves
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-11-16

5.  Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study.

Authors:  Marc Miravitlles; Juan José Soler-Cataluña; Joan B Soriano; Francisco García-Río; Pilar de Lucas; Inmaculada Alfageme; Ciro Casanova; José Miguel Rodríguez González-Moro; M Guadalupe Sánchez-Herrero; Julio Ancochea; Borja G Cosío
Journal:  Respir Res       Date:  2022-03-05

Review 6.  The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives.

Authors:  Juan de Dios Caballero; Rafael Cantón; Manuel Ponce-Alonso; Marta María García-Clemente; Elia Gómez G de la Pedrosa; José Luis López-Campos; Luis Máiz; Rosa Del Campo; Miguel Ángel Martínez-García
Journal:  Microorganisms       Date:  2022-04-13

7.  Assessment of Airway Remodeling Using Endobronchial Ultrasound in Asthma-COPD Overlap.

Authors:  Krzysztof Sładek; Jerzy Soja; Karolina Górka; Iwona Gross-Sondej; Jacek Górka; Tomasz Stachura; Kamil Polok; Natalia Celejewska-Wójcik; Sławomir Mikrut; Anna Andrychiewicz
Journal:  J Asthma Allergy       Date:  2021-06-14

8.  Immune Cell Subtypes and Cytokines in Lung Tumor Microenvironment: Influence of COPD.

Authors:  Jun Tang; Daniel Ramis-Cabrer; Víctor Curull; Xuejie Wang; Liyun Qin; Mercé Mateu-Jiménez; Xavier Duran; Lara Pijuan; Alberto Rodríguez-Fuster; Rafael Aguiló Espases; Esther Barreiro
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

9.  Associations among chronic obstructive pulmonary disease with asthma, pneumonia, and corticosteroid use in the general population.

Authors:  Jun-Jun Yeh; Cheng-Li Lin; Chia-Hung Kao
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

10.  Variability of blood eosinophil count and prognosis of COPD exacerbations.

Authors:  Sandra Martínez-Gestoso; María-Teresa García-Sanz; Uxío Calvo-Álvarez; Liliana Doval-Oubiña; Sandra Camba-Matos; Francisco-Javier Salgado; Xavier Muñoz; Purificación Perez-Lopez-Corona; Francisco-Javier González-Barcala
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.